Company Overview and News


Add AVIR
to your dashboard

Headline News

AVIR / Aviragen Therapeutics, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2017-11-09 fintel.io
Aviragen Therapeutics, Inc. (NASDAQ:AVIR) has 35 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 15,177,565 shares. Largest shareholders include East Hill Management Company, Llc, Krensavage Asset Management, LLC, SC Fundamental Value Fund, L.P., Armistice Capital, Llc, and Renaissance Technologies LLC. (49-3)

Corporate News Blog - Aviragen Enters Into Merger Agreement with Vaxart

2017-11-01 accesswire
LONDON, UK / ACCESSWIRE / November 1, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Aviragen Therapeutics, Inc, (NASDAQ: AVIR) (""Aviragen), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=AVIR. The Company announced on October 30, 2017, that it has entered into a definitive merger agreement with Vaxart Inc. (74-2)

Earnings Review and Free Research Report: Aviragen Reported its Q4 and Full Year FY17 Results

2017-09-25 accesswire
LONDON, UK / ACCESSWIRE / September 25, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Aviragen Therapeutics, Inc. (NASDAQ: AVIR), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=AVIR, following the Company's reporting of its financial results on August 31, 2017, for the fourth quarter fiscal 2017 (Q4 FY17) and full year 2017 (FY17). The Atlanta, Georgia-based Company's net loss narrowed during the reported quarter. (88-0)

Technical Insights on Communication Equipment Stocks -- Nokia, ShoreTel, Aerohive Networks, and Barracuda Networks

2017-09-21 prnewswire
If you want a Stock Review on NOK, SHOR, HIVE, or CUDA then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Wednesday, benchmark US indices were in mixed as the NASDAQ Composite closed the trading session down 0.08%; the Dow Jones Industrial Average edged 0.19% higher; and the S&P 500 was up 0.06%. US markets saw five out of nine sectors finishing the day in green and 4 in red. (107-1)

Stocks Under Scanner in the Biotech Space -- Aviragen Therapeutics, Blueprint Medicines, Calithera Biosciences, and Cytokinetics

2017-09-21 prnewswire
If you want a Stock Review on AVIR, BPMC, CALA, or CYTK then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Wednesday, September 20, 2017, the NASDAQ Composite ended the trading session at 6,456.04, down 0.08%; the Dow Jones Industrial Average edged 0.19% higher, to finish at 22,412.59; and the S&P 500 closed at 2,508.24, slightly advancing 0. (116-0)

BRIEF-SC Fundamental Value Fund LP reports 5.01 pct stake in Aviragen Therapeutics Inc as of June 21

2017-06-30 reuters
* SC Fundamental Value Fund Lp reports 5.01 percent stake in Aviragen Therapeutics Inc as of June 21 - SEC filing Source text - (bit.ly/2tsaxus) Further company coverage:

BRIEF-East Hill Management says Aviragen Therapeutics "should wind up its business and liquidate"

2017-06-19 reuters
* East Hill Management says Aviragen Therapeutics "should abandon all of its plans to explore strategic alternatives and instead should wind up its business and liquidate"

Blog Coverage Aviragen to Explore Strategic Alternatives; Cuts Headcount by 25%

2017-04-05 accesswire
LONDON, UK / ACCESSWIRE / April 5, 2017 / Active Wall St. blog coverage looks at the headline from Aviragen Therapeutics, Inc. (NASDAQ: AVIR) as the Company announced on April 05, 2017, that based on a review of the status of its internal programs, resources and capabilities, it plans to explore a wide range of strategic alternatives that include a business combination or strategic merger, in-licensing clinical stage programs, an acquisition, or other transaction that would complement the Company's current pipeline and could maximize both near- and long-term value for its shareholders.

Aviragen Slashes 25% of Workforce, Reviewing Strategic Alternatives

2017-04-04 biospace
ATLANTA, April 04, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a company focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options, today announced that based on a review of the status of its internal programs, resources and capabilities, it plans to explore a wide range of strategic alternatives that include a business combination or strategic merger, in-licensing clinical stage programs, an acquisition, or other transaction that would complement the Company’s current pipeline and could maximize both near and long-term value for our shareholders.

Aviragen Cutting Jobs, Exploring Strategic Alternatives

2017-04-04 genengnews
If You’re Up Against Cancer, Don’t Fight Fair. The Name of The Game Is Combination Therapy

4 Stocks That Are Breaking Hearts on Valentine’s Day

2017-02-14 247wallst
Valentine’s Day is here and it has been an incredible day for quite a few companies. The S&P 500, Nasdaq and Dow have been performing lovely in just the past week, hitting new all-time highs. But like any relationship, this is a team effort, and there have been a few companies holding back this rally. In fact, in Tuesday’s session alone some companies have downright broken shareholders’ hearts.

Aviragen Tanks Some More After Reporting a Second Trial Failure This Month

2017-02-14 biospace
ATLANTA, Feb. 13, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics (NASDAQ:AVIR), a company focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options, today announced top-line data from its Phase 2b SPIRITUS trial, a multi-center, randomized, double-blind, placebo-controlled, dose-ranging study of vapendavir in moderate to severe asthmatics with a rhinovirus (RV) infection.

Aviragen Antiviral Drug Vapendavir Fails Phase IIb Study in Asthma Patients

2017-02-14 genengnews
Aviragen Therapeutics reported its second Phase II trial disappointment in as many weeks. The firm said that the Phase IIb SPIRITUS study evaluating the oral capsid-binding antiviral drug, vapendavir, in asthma patients with rhinovirus (RV) infection, failed to meet its primary endpoint. At the start of this month Aviragen reported on topline Phase IIa data indicating that a second clinical candidate, BTA585, failed to reduce viral load in adults challenged intranasally with syncytial virus (RSV).

HC Wainwright Reaffirms “Buy” Rating for Aviragen Therapeutics, Inc. (AVIR) - Zolmax

2017-02-10 zolmax
HC Wainwright reiterated their buy rating on shares of Aviragen Therapeutics, Inc. (NASDAQ:AVIR) in a research report report published on Monday. They currently have a $5.00 price objective on the stock.

Stock Research Report

Aviragen Therapeutics is focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three Phase 2 clinical stage compounds: BTA074, an antiviral treatment for condyloma caused by human papillomavirus types 6 & 11; vapendavir, a capsid inhibitor for the prevention or treatment of rhinovirus (RV) upper respiratory infections; and BTA585 (enzaplatovir), a fusion protein inhibitor in development for the treatment of respiratory syncytial virus infections. The company also have a preclinical RSV non-fusion inhibitor program.

In April 2017, the company engaged Stifel, Nicolaus and Company, Incorporated (“Stifel”) as its advisor to assist with the exploration of strategic alternatives (the “Strategic Review”). Stifel is providing a range of advisory services aimed to enhance stockholder value. The alternatives to be considered may include, but are not l...

Click for full article
CUSIP: 053761102